Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Annals of Oncology

Topics

Medicine

Cancer Oncology

Epidemiology

Immunology

Internal Medicine

Show all topics

DOI

10.1016/j.annonc.2021.03.005

License

CC-BY-NC-ND

Other Formats

PDF